Naismith Lab

Robert T. Naismith, MD

Robert T. Naismith, MD, is interested in improving the use of imaging modalities to better prognosticate and care for those with multiple sclerosis. The current focus is on MR Diffusion Tensor Imaging as a pathologic surrogate for axonal loss. This includes studies in the optic nerves, brain and spinal. The studies include measurements and outcomes that are important to patients and have relevance for implementing in clinical practice.

Principal investigator

Robert T. Naismith, MD

Robert T. Naismith, MD

Professor of Neurology
Adult, Neuroimmunology


  Naismith lab

 
Top areas of adult care: multiple sclerosis, demylination, NMO

Research profile
Clinical profile

Recent publications

  • Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers
    Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centersConway, D. S., Nicholas, J. A., Thompson, N. R., Mowry, E. M. & Naismith, R. T., Feb 2025, In: Multiple Sclerosis and Related Disorders. 94, 106272.Research output: Contribution to journal › Article › peer-review
  • A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosis
    A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosisJiang, X., McGinley, M., Johnston, J., Alberts, J., Bermel, R., Ontaneda, D., Naismith, R. T., Hyde, R., Levitt, N., van Beek, J., Sun, Z., Campbell, N. & Barro, C., Jan 2025, In: Multiple Sclerosis Journal. 31, 1, p. 81-92 12 p.Research output: Contribution to journal › Article › peer-review
  • Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study
    Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I studyNewsome, S. D., Goldstick, L., Robertson, D. S., Bowen, J. D., Naismith, R. T., Townsend, B., Figueiredo, C., Kletzl, H., Giraudon, M., Bortolami, O., Zecevic, D., Giacobino, C., Clinch, S., Shen, Y. A., Deol-Bhullar, G. & Bermel, R. A., Dec 2024, In: Annals of Clinical and Translational Neurology. 11, 12, p. 3215-3226 12 p.Research output: Contribution to journal › Article › peer-review
  • A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network
    A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research networkHersh, C. M., Sun, Z., Conway, D. S., Sotirchos, E. S., Fitzgerald, K. C., Hua, L. H., Ziemssen, T., Naismith, R. T., Pellegrini, F., Grossman, C. & Campbell, N., Nov 2024, In: Multiple Sclerosis and Related Disorders. 91, 105847.Research output: Contribution to journal › Article › peer-review
  • Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients
    Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis PatientsBrier, M. R., Schindler, S. E., Salter, A., Perantie, D., Shelley, N., Judge, B., Keefe, S., Kirmess, K. M., Verghese, P. B., Yarasheski, K. E., Venkatesh, V., Raji, C. A., Gordon, B. A., Bateman, R. J., Morris, J. C., Naismith, R. T., Holtzman, D. M., Benzinger, T. L. S. & Cross, A. H., Sep 2024, In: Annals of neurology. 96, 3, p. 453-459 7 p.Research output: Contribution to journal › Article › peer-review
Complete bibliography